Morgan Stanley Maintains Overweight on Evommune, Lowers Price Target to $26
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Judah Frommer maintains Evommune (NYSE:EVMN) with a Overweight and lowers the price target from $55 to $26.
Morgan Stanley analyst Judah Frommer maintains Evommune (NYSE:EVMN) with a Overweight and lowers the price target from $55 to $26.